Cue Biopharma is trading 5.9% up now at $28.34, with continued biotechnology-sector momentum the strongest identified driver; XBI rose 2.06% during regular trading.
- The stock extended its 15.44% gain on August 25.
- No new company-specific announcement dated August 26 was identified.
- Cue’s latest major release, dated August 14, outlined CUE-221 clinical milestones and a completed $50 million private placement, but did not directly link those developments to today’s move.